Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls

References

• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
   Google Scholar
• Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001; 12: 413–9
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. [Review]. Lancet 1998; 351: 1881–3
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9
   PubMed Web of Science ®Google Scholar
• The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479–86
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25: 1253–4
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130–9
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731–6
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004; 36: 186–91
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625–30
   PubMed Web of Science ®Google Scholar
• Schumacher A, Lerkerod AB, Seljeflot I, Sommervoll L, Holme I, Otterstad JE, et al. Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals. J Clin Microbiol 2001; 39: 1859–64
   PubMed Web of Science ®Google Scholar
• Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Groop L. Hyperproinsulinaemia of type II diabetes is not present before the development of hyperglycaemia. Diabetes Care 1994; 17: 1307–10
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726–35
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9
   PubMed Web of Science ®Google Scholar
• Chu JW, Abbasi F, Beatty GW, Khalili M, Koch J, Rosen A, et al. Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients. Metabolism 2003; 52: 858–61
   PubMed Web of Science ®Google Scholar
• Kramer MS. Confounding Bias. Clinical Epidemiology and Biostatistics, a primer for clinical investigators and decision-makers. Springer-Verlag, Berlin 1991; 53
   Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9
   PubMed Web of Science ®Google Scholar
• Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinaemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932–7
   PubMed Web of Science ®Google Scholar
• Kino T, Chrousos GP. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome?. Ann N Y Acad Sci 2004; 1024: 153–67
   PubMed Web of Science ®Google Scholar
• Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1–8
   PubMed Web of Science ®Google Scholar
• Behrens GM, Boerner AR, Weber K, van den HJ, Ockenga J, Brabant G, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002; 110: 1319–27
   PubMed Web of Science ®Google Scholar
• Torriani M, Hadigan C, Jensen ME, Grinspoon S. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol 2003; 95: 1005–10
   PubMed Web of Science ®Google Scholar
• Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumour necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312–21
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–71
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Tonstad S, Sandvik L, Bruun JN. Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/l in non-nucleoside reverse transcriptase inhibitor recipients. Int J STD AIDS 2005; 16: 365–9
   PubMed Web of Science ®Google Scholar